Bryan Richard Sasmita

Dr. Bryan Richard Sasmita

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
BSBryan Richard Sasmita
Bryan Richard Sasmita
YZYuansong Zhu
Yuansong Zhu
HGHongbo Gan
Hongbo Gan
XHXiankang Hu
Xiankang Hu
YXYuzhou Xue
Yuzhou Xue
SLSuxin Luo
Suxin Luo

18 January 2024 in Global Heart
Verified
Journal Article
Open access
PDF file
BSBryan Richard Sasmita
Bryan Richard Sasmita
YZYuhe Zhao
Yuhe Zhao
MGMing Gong
Ming Gong
SLSu Xin Luo
Su Xin Luo
BHbi huang
bi huang
Introduction: Chronic fluid accumulation or congestion is considered an important pathophysiologic mechanism in heart failure, leading to cardinal symptoms such as dyspnea, pulmonary congestion, and pitting edema. Edema index (EI) recently emerged as a surrogate for extracellular volume status and has been proven to be able to reflect one’s congestion status. In this study, we aimed to evaluate the prognostic value of EI in patients with chronic heart failure (CHF). Methods: A total of 401 consecutive patients with CHF between August 2019 and October 2021 were prospectively enrolled. EI was obtained by InBody S10. The primary endpoint was long-term all-cause and cardiovascular mortality. Results: Patients with high EI (>0.397) tended to be older, presented with atrial fibrillation, have higher N-terminal brain natriuretic peptide, and have higher creatinine (all p < 0.05). During a median follow-up of 1200 days, the all-cause and cardiovascular mortality rate was significantly higher in the high EI group compared to the low EI group (all-cause mortality rate 43.8% vs. 30.3%, p < 0.001, and cardiovascular mortality rate 17.5% vs. 13.0%, p < 0.001, respectively). In the multivariate Cox proportional hazard analysis, EI > 0.397 was an independent predictor for both all-cause mortality (HR 1.959; 95% CI 1.304, 2.944; p = 0.001) and cardiovascular mortality (HR 2.051; 95% CI 1.276, 3.296; p = 0.003). Conclusions: Admission EI could be used as a marker for predicting long-term mortality in patients with CHF, and higher EI was associated with an increased risk of all-cause and cardiovascular mortality. Furthermore, EI-guided management could be a promising therapy in patients with CHF.

27 February 2021 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
BSBryan Richard Sasmita
Bryan Richard Sasmita
BHBi Huang
Bi Huang
GLGang Liu
Gang Liu
YYYuan Yang
Yuan Yang
SLSu Xin Luo
Su Xin Luo
Elevated resting heart rate in chronic heart failure (HF) patients has been associated with higher mortality and poor prognosis. Ivabradine is a new pure bradycardic agent that has been used to treat angina or heart failure reduced ejection fraction (HFrEF) with sinus heart rate above 70 beats per minute. However, the effect of ivabradine for chronic HF patients on rehospitalization and cardiac function is still inconsistent. Thus, this meta‐analysis aimed to elucidate the effect of Ivabradine in chronic HFrEF patients. We systematically searched PubMed, Medline, Clinical Trials.gov, and The Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) of ivabradine with search terms Ivabradine (MeSH Terms), chronic heart failure and beta‐blocker. The primary endpoints of the study include the impact of Ivabradine on heart rate, left ventricle ejection fraction (LVEF), left ventricular remodeling, exercise capacity, and quality of life (QoL) in patients with chronic HFrEF. Secondary endpoints were safety analysis of Ivabradine including cardiovascular mortality, worsening HF readmission, visual disturbances, and asymptomatic bradycardia. The analysis was done by Review Manager 5.4 Analyzer, to analyze the mean differences (MD) for continuous data and risks ratio (RR) for dichotomous data. A total of six RCTs and one subgroup analysis showed add of Ivabradine to standard HF therapy was associated with greater resting heart rate reduction (MD = −9.57; 95% CI ‐11.15, −8.00), improved LVEF (MD = 3.89; 95% CI 2.61, 5.17), left ventricular reverse remodeling improvement (MD = −3.73; 95% CI ‐4.25, −3.21, LVESV; MD = −17.00, 95%CI ‐29.65, −4.35, LVEDD; MD = −1.43, 95%CI ‐2.78, −0.08, LVEDV; MD = −14.75, 95%CI ‐34.36, 4.87), increased exercise capacity (exercise duration; MD = 8.52; 95%CI 0.09, 16.94), and significant reduction on rehospitalization due to worsening HF (RR = 0.76, 95%CI 0.69, 0.84). However, Ivabradine has no significant effect on the quality of life (MD = 0.65; 95%CI ‐10.52, 11.82), and cardiovascular mortality (RR = 0.92; 95%CI 0.82, 1.03). Moreover, there were some events of visual disturbances and asymptomatic bradycardia observed in the Ivabradine group compared to the placebo group (RR = 4.76; 95%CI 3.03, 7.48; RR = 3.78; 95%CI 2.77, 5.15, respectively). Addition of Ivabradine to standard HF therapy is associated with cardiac function improvement, reduction on worsening HF readmission, greater HR reduction, and better exercise capacity in chronic HFrEF patients, although it cannot reduce cardiovascular mortality or improve the quality of life.

18 July 2024 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
MGMing Gong
Ming Gong
BSBryan Richard Sasmita
Bryan Richard Sasmita
YZYuansong Zhu
Yuansong Zhu
SCSiyu Chen
Siyu Chen
YWYaxin Wang
Yaxin Wang
BHbi huang
bi huang
Background: Acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) carries a high mortality risk. Inflammation and nutrition are involved in the pathogenesis and prognosis of both AMI and CS. The advanced lung cancer inflammation index ratio (ALI) combines the inflammatory and nutritional status. Our present study aimed to explore the prognostic value of ALI in patients with CS following AMI. Methods: In total, 217 consecutive patients with AMI complicated by CS were divided into two groups based on the ALI admissions cut-off: ≤12.69 and >12.69. The primary endpoint of this study was 30-day all-cause mortality. The secondary endpoints were gastrointestinal hemorrhage and major adverse cardiovascular events (MACEs), including 30-day all-cause mortality, atrioventricular block, ventricular tachycardia/ventricular fibrillation, and nonfatal stroke. The association of ALI with the study endpoints was analyzed by Cox regression analysis. Results: During the 30-day follow-up period after admission, 104 (47.9%) patients died and 150 (69.1%) suffered MACEs. The Kaplan–Meier analysis revealed significantly higher cumulative mortality and lower MACE rates in the low-ALI group compared to the high-ALI group (both log-rank p < 0.001). The 30-day mortality rate was significantly higher in patients with ALI ≤12.69 compared to ALI >12.69 (72.1% vs. 22.6%; p < 0.001). Furthermore, the incidence of MACEs was higher in patients with ALI ≤12.69 (85.6% vs. 51.9%; p < 0.001). The receiver operating curve showed that ALI had a modest predictive value (area under the curve [AUC]: 0.789, 95% confidence interval [CI]: 0.729, 0.850). After multivariable adjustment, ALI ≤12.69 was an independent predictor for both 30-day all-cause mortality (hazard ratio [HR]: 3.327; 95% CI: 2.053, 5.389; p < 0.001) and 30-day MACEs (HR: 2.250; 95% CI 1.553, 3.260; p < 0.001). Furthermore, the addition of ALI to a base model containing clinical and laboratory data statistically improved the predictive value. Conclusions: Assessing ALI levels upon admission can provide important information for the short-term prognostic assessment of patients with AMI complicated by CS. A lower ALI may serve as an independent predictor of increased 30-day all-cause mortality and MACEs.

22 November 2022 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
FAFabrice Boris Awadji
Fabrice Boris Awadji
BHbi huang
bi huang
BSBryan Richard Sasmita
Bryan Richard Sasmita
SOSamuel Chigbo Obiegbusi
Samuel Chigbo Obiegbusi
ACArmin Czika
Armin Czika
Gang LiuGang Liu
Gang Liu
Background: Imbalance of testosterone/estradiol ratio are frequently reported to be associated with the risk of cardiometabolic diseases; however, studies have yet to report the testosterone/estradiol ratio and its relationship to cardiometabolic diseases in women at menopause transition. This study aimed to explore the association between testosterone/estradiol ratio with cardiometabolic diseases in women during their menopausal transition age. Methods: 551 women aged from 45 to 55 years old were involved in this study. Their baseline information, disease comorbidity, blood biochemical tests, echocardiography and serum sex hormones were collected. Women were categorized by tertile distribution of testosterone/estradiol ratio. We used binary logistic regression model (for odds ratio) and poissoon loglinear model (for prevalence ratio) to evaluate the association between testosterone/estradiol ratio with cardiometabolic diseases. Results: The mean age of the study population was 48.6 ± 3.5 years old. Taking testosterone/estradiol ratio <3.9 as reference, the odds ratio with 95% confidence interval across the tertile groups for obesity were: 1.0 (reference), 2.32 (0.96–5.64), 4.70 (1.75–12.67) (p for trend = 0.002); for hypertension were: 1.0 (reference), 2.37 (1.45–3.86), 2.02 (1.12–3.62) (p for trend = 0.013); for cardiometabolic diseases were: 1.0 (reference), 2.29 (1.47–3.56), 2.34 (1.37–3.99) (p for trend = 0.013), compared with the prevalence ratio of 1.0 (reference), 1.64 (1.26–2.15), 1.65 (1.21–2.23) (p for trend = 0.001), respectively. Conclusions: Higher testosterone/estradiol ratio was associated with elevated prevalence of cardiometabolic diseases in women at menopause transition period.

8 July 2022 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
YZYuansong Zhu
Yuansong Zhu
BSBryan Richard Sasmita
Bryan Richard Sasmita
YXYuzhou Xue
Yuzhou Xue
YJYi Jiang
Yi Jiang
BHbi huang
bi huang
SLSu Xin Luo
Su Xin Luo